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Abstract: Atherosclerotic coronary artery disease (CAD) results from build-up of cholesterol-rich
plaques in the walls of the coronary arteries and is a leading cause of death. Inflammation is central
to atherosclerosis. Uncontrolled inflammation makes coronary plaques “unstable” and vulnerable to
rupture or erosion, leading to thrombosis and myocardial infarction (MI). As multiple inflamed plaques
often co-exist in the coronary system, patients are at risk of repeated atherothrombotic cardiovascular
events after MI, with rates of 10–12% at one year and 18–20% at three years. This is largely
because current therapies for CAD, such as lipid-lowering statins, do not adequately control plaque
inflammation. New anti-atherosclerotic agents are therefore needed, especially those that better target
inflammation. The recent positive results for the anti-interleukin-1-beta (IL-1β) monoclonal antibody,
Canakinumab, in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS)
clinical trial has provided a major stimulant to the field. It highlights that not only is inflammation
important from a pathogenic and risk prediction perspective in CAD, but that reducing inflammation
can be beneficial. The challenge is now to find the best strategies to achieve this in real-world practice.
This review outlines the role that inflammation plays in atherosclerosis and provides an update on
anti-inflammatory therapies currently being investigated to target atherosclerosis.
Keywords: inflammation; atherosclerosis; C-reactive protein; canakinumab; methotrexate;
colchicine; interleukin
1. Introduction
Cardiovascular disease (CVD) remains a leading cause of death, morbidity and health economic
burden worldwide. It currently accounts for more than 17.6 million deaths each year and this
number is projected to exceed 23.6 million by 2030 [1]. Atherosclerotic coronary artery disease (CAD),
the underlying pathology in the majority of cardiovascular complications such as myocardial infarction
(MI), is still the major cause of cardiovascular mortality [1]. One of the greatest triumphs of preventative
cardiology has been the identification and subsequent aggressive control of traditional risk factors for
atherosclerosis, such as hypertension, diabetes, cigarette smoking, and elevated low-density lipoprotein
cholesterol (LDL-C). As a result, we have seen a dramatic decrease in the incidence of MI by up to 40% in
many Western nations that have embraced a preventative approach to CAD [2]. One important example
of this is the use of cholesterol-lowering hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors, collectively known as statins, that reduce the incidence of major adverse cardiovascular
events (MACE) by 25% to 40% in susceptible individuals with elevated LDL-C [3]. However, despite
our best attempts to manage traditional risk factors with contemporary approaches, MACE continue
to occur at unacceptable rates in patients with established CAD, with event rates of 10–12% at one
year and 18–20% at three years after an index myocardial infarction (MI) [4]. This is largely because
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atherosclerosis is a complex disease process whose pathogenic basis extends far beyond intimal
infiltration of cholesterol. In particular, numerous converging lines of clinical and experimental
evidence show that inflammation is a key player in its initiation, progression and eventual thrombotic
manifestations [5]. This review focuses on the role that inflammation plays in atherosclerosis and
provides a timely update on the status of anti-inflammatory therapeutic approaches that are being
investigated to target atherosclerosis and its lethal sequelae.
2. Inflammation in the Pathophysiology of Atherosclerosis
Atherosclerosis is widely recognised as being a chronic inflammatory disease of blood vessels
triggered by LDL-C accumulation, and characterised by formation of complex subintimal plaques that
restrict luminal blood flow and have propensity to rupture or erode leading to thrombotic occlusion
and tissue infarction. An early mechanism in atherogenesis is exposure of the intimal endothelium
to noxious stimuli, such as hypercholesterolaemia, hypertension and pro-inflammatory cytokines,
that disrupt its ability to function as a permeability barrier and cause it to become ‘activated’. In their
activated state, blood vessels are prone to the uptake of lipoproteins, particularly ApoB containing
LDL-C, from the circulating blood. These lipoproteins are subsequently retained in the arterial wall
following interactions with subendothelial proteoglycans in the extracellular matrix, where they
undergo chemical modifications. One such modification is oxidation which occurs secondary to
interactions between lipoproteins and locally released reactive oxygen species (ROS), pro-oxidative
enzymes and lipid oxygenases.
Another important feature observed consistently in early plaque formation is leukocyte recruitment
to the vessel wall, which occurs in conjunction with lipoprotein uptake (Figure 1). After their activation,
intimal endothelial cells, which normally resist the attachment of leukocytes in the bloodstream,
increase their expression of leukocyte adhesion molecules, such as vascular cell adhesion molecule-1
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) [6,7]. This resultant change in receptor
expression promotes the extravasation of leukocytes, particularly neutrophils and monocytes, from the
circulating blood into the subendothelial space. The initial adhesion of leukocytes to the activated
endothelium is mediated by selectin-dependent adhesion molecules, such as E-selectin and P-selectin.
Following this initial tethering, leukocytes form tighter adhesions via the binding of VLA-4 (very late
antigen-4) on the leukocyte to its complementary ligands on the activated endothelial cell, VCAM-1
and ICAM-1. The importance of leukocyte adhesion in early plaque formation is supported by animal
work showing significant reductions in lesion size in ICAM-1 and P-selectin null mice, as well as mice
with genetic deficiencies in VCAM-1 expression [8–11].
Once resident in the arterial wall, monocytes differentiate into macrophages in the presence
of growth factors, such as macrophage-colony stimulating factor (M-CSF) (Figure 1). Macrophages
ingest modified LDL-C particles, including oxidised LDL (oxLDL), to become lipid-laden foam cells.
The aggregation of foam cells results in a yellow coloured ‘fatty streak’ in the vessel wall and with it,
the first macroscopic signs of atherosclerotic disease. Fatty streaks, also known as intimal xanthomas,
have been identified in a third of children under the age of nine, and become increasingly prevalent
by the age of 20–29 while remaining asymptomatic [12,13]. Uptake of oxLDL by monocyte-derived
macrophages occurs primarily through a family of ‘scavenger receptors’ (SRs) that is upregulated
during differentiation. Binding of oxLDL to SRs results in internalisation of these biochemically
modified lipoproteins into cytoplasmic lipid droplets. While numerous SRs have been discovered,
studies have shown that CD36 (cluster of differentiation-36) and SR-A1 (scavenger receptor type 1)
account for up to 90% of oxLDL uptake by macrophages [14].
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Figure 1. Infiltration of low-density lipoprotein (LDL) and formation of macrophage foam cells in
the arterial wall. In individuals with hypercholesterolaemia, elevated levels of LDL-C are prone to
infiltration and retention in the arterial wall. Monocytes recruited into the arterial wall differentiate
into macrophages on stimulation by macrophage colony stimulating factor (M-CSF). Modified LDL
particles are then taken up by macrophages via scavenger receptors. Accumulation of lipids in the
macrophage results in the formation of lipid-laden foam cells leading to the release of pro-inflammatory
cytokines. CD36, cluster of differentiation-36; ICAM, intercellular cell adhesion molecule 1; IL-1β,
interleukin-1-beta; LDL-C, low-density lipoprotein cholesterol; M-CSF, macrophage colony stimulating
factor; oxLDL, oxidised low density lipoproteins; TNF-α, tumor necrosis factor alpha; SR-A1, scavenger
receptor type 1; VCAM-1, vascular cell adhesion molecule 1.
At first the initial uptake of oxLDL by macrophages to become foam cells is beneficial as it
sequesters potentially damaging lipoproteins. However, over time the ability for foam cells to handle
and process the lipoproteins is exceeded. This causes endoplasmic reticulum stress leading to ROS
production which triggers an apoptotic cascade. While in part due to uncontrolled lipoprotein uptake,
impairment of cholesterol efflux by foam cells also contributes to their demise [15]. This leads to the
release of an array of pro-inflammatory cytokines, such as interleukin-1-alpha (IL-1α), IL-1β, IL-6,
tumor necrosis factor-alpha (TNF-α) and matrix metalloproteinases (MMPs), which further exacerbates
atherosclerosis by promoting immune cell infiltration. Furthermore, inefficient clearance of dead cell
components, by a process called efferocytosis, can result in the accumulation of cellular debris and
lipids. This predisposes the plaque to form a necrotic lipid-rich core that is highly thrombogenic [16].
The natural progression of atherosclerotic plaque from an intimal fatty streak to a fibrous
atheromatous plaque is due to the recruitment of smooth muscle cells (SMC) from the tunica media—the
middle layer of the artery wall–into the tunica intima. The migration of SMC occurs following the release
of pro-inflammatory cytokines and proteolytic enzymes by activated endothelial cells, macrophages
and foam cells that degrade the supporting extracellular framework. These cytokines then provide
a chemotactic signal for the migration of SMC and stimulate a shift in their phenotypic profile from
quiescent to actively synthetic. Once in the intima, SMC proliferate and produce an array of extracellular
matrix (ECM) proteins, including type 1 and type 3 collagen, and proteoglycans that are thought to be
pivotal to plaque remodeling and stabilisation [17,18]. The accumulation of SMC-derived ECM results
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in the formation of a fibrous cap that overlies the plaque. Collagen degradation leading to thinning of
the fibrous cap has been found to be an important contributor to plaque rupture.
While much has been elaborated on the role of macrophages in atherosclerosis, cells of the
adaptive immune system, particularly T lymphocytes and B lymphocytes, are also important mediators
of atherosclerosis [19]. Albeit at fewer numbers, these lymphocytes, particularly T lymphocytes,
are seen in plaques as early as monocytes and appear to have key roles in regulating the inflammatory
response elicited by macrophages during atherogenesis. T lymphocytes exhibit diverse functions
in atherosclerosis. T-helper-1 (Th-1) lymphocytes secrete pro-inflammatory cytokines, such as
interferon-gamma (IFN-γ), IL-2 and TNF-α, which activate macrophages, endothelial cells and SMC,
therefore propagating and accelerating atherosclerosis [20]. On the other hand, regulatory-T (T-reg)
lymphocytes are thought to downregulate the inflammatory process by secreting anti-inflammatory
cytokines, such as IL-10 and transforming growth factor-beta (TGF-β) [21]. Similar to T lymphocytes, B
lymphocyte functionality appears to be heavily dependent on the specific cell subtype. B1 lymphocytes,
which may produce antibodies in response to an atherogenic antigen, appear to be protective against
atherosclerosis [22,23], whereas B2 lymphocytes may exacerbate atherogenesis through the secretion of
pro-inflammatory cytokines and activation of Th-1 lymphocytes [24,25]. The importance of the adaptive
immune system has been demonstrated in experimental models of atherosclerosis which showed a 40%
to 80% reduction in atherosclerotic disease burden in T and B lymphocyte deficient mice [26]. While
further research is required to determine the extent of their involvement in atherosclerosis, it is likely
that the net effect of T and B lymphocytes is dependent on the balance between their pro-inflammatory
and anti-inflammatory subsets.
3. Burden of Cardiovascular Disease in Chronic Inflammatory Diseases
It has long been acknowledged that diseases characterised by chronic inflammation are
disproportionately burdened by CVD with rheumatological conditions exemplifying this link [27].
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterised by inflammatory
polyarthritis and progressive joint destruction that affects up to 1% of the general population [28].
Accumulating evidence indicates that individuals with RA have a significantly increased risk of
mortality with CVD accounting for over a third of deaths [29,30]. Recent meta-analyses of observational
studies report that RA increases the risk of incident cardiovascular events and cardiovascular-related
mortality by 48% and 50% respectively, compared to the general population [31,32]. This is comparable
to the magnitude of risk imparted on CVD by diabetes mellitus [33]. Specific to CAD, patients with RA
are 68% more likely to have a MI compared to those without RA [31]. This result has recently been
supported by a prospective population-based cohort study that reported a 43% increase risk of MI in
patients with RA [34]. Furthermore, it appears that the increased incidence of CVD in patients with RA
is independent of traditional risk factors [35]. This suggests that additional mechanisms account for
the excess rates of CVD observed in RA with recent evidence implicating chronic inflammation as the
most likely culprit [36,37].
In addition to RA, other systemic diseases characterised by chronic inflammation have also been
associated with an increased risk of CVD [38–40]. These include psoriasis, ankylosing spondylitis,
systemic lupus erythematosus as well as inflammatory bowel disease. The pathogenesis of these
conditions share common inflammatory pathways to those involved in the development and progression
of atherosclerosis. For example, the pathogenesis of psoriasis, which is an immune-mediated disease
affecting the skin and joints, is primarily mediated by T lymphocytes; specifically, those displaying
the Th-1 phenotype. Similar to Th-1 lymphocytes in atherosclerotic plaque, Th-1 lymphocytes in
psoriatic plaques release pro-inflammatory cytokines, such as TNF-α, IL-1β and IL-6, that activate
cells of the innate immune system such as macrophages and neutrophils [41]. Therefore, it is these
shared pathways that may underlie and explain the increased rates of CVD observed in chronic
inflammatory conditions. Furthermore, the discovery of auto-antibodies against oxLDL and growing
evidence of autoimmune-like involvement of the adaptive immune system has led to consideration that
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atherosclerosis may in-part be an autoimmune condition or at least an auto-inflammatory mediated
disease [42].
4. Beyond Statins: Where to Now for Anti-Atherosclerotic Therapies?
As highlighted earlier, risk modification with statin therapy is now a common practice in both the
primary and secondary prevention of atherosclerotic CVD. Statins have previously been shown to
exhibit anti-inflammatory effects in addition to lowering lipid levels. Trials attempting to quantify
overall inflammatory burden often utilise high sensitivity C-reactive protein (hsCRP), as it is an
increasingly available and cost-effective test that captures most of the upstream inflammatory activity.
The anti-inflammatory effect of statins was formally tested in the JUPITER (Justification for the Use
of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) trial [43]. In this study,
participants with LDL-C levels < 3.4 mmol/L and elevated hsCRP > 2 mg/L were randomised to receive
either 20 mg/day of rosuvastatin or placebo. Of the 17,803 apparently healthy individuals recruited,
those treated with rosuvastatin had a 44% risk reduction in first ever cardiovascular events compared
to the placebo group (HR 0.56; 95% CI 0.46–0.69; p < 0.00001). Relevant to the inflammation hypothesis
of atherosclerosis, rosuvastatin was shown to lower hsCRP levels by 47% from a median of 4.2 mg/L at
baseline to 2.2 mg/L at 12-month follow up. Therefore, it appears that patients who receive standard
therapy with statins as part of secondary prevention may obtain some degree of anti-inflammatory
coverage. Despite this, atherosclerotic events continue to occur at alarming rates, and it is thought that
residual inflammatory risk may be an important driving force behind this. Analysis of the PROVE-IT
(Pravastatin or Atorvastatin Evaluation and Infection Therapy) trial showed that of the 2099 patients
who had a history of preceding acute coronary syndrome and were given 80 mg atorvastatin, 44%
achieved reductions to target in both LDL-C (<1.8 mmol/L) and hsCRP (<2 mg/L) [44,45]. However,
29%, 13% and 14% of patients were left with suboptimal residual inflammatory risk (hsCRP > 2 mg/L),
residual cholesterol risk (LDL-C > 1.8 mmol/L) or both, respectively. These results suggest that
recurrent coronary events may be driven by different biological processes that require different
management strategies to address. Using the same thresholds for residual risk as PROVE-IT, similar
relative proportions were identified in secondary analyses of the IMPROVE-IT (Improved Reduction
of Outcomes: Vytorin Efficacy International) trial [46]. This study randomised 15,179 stable patients
with acute coronary syndrome to either 40 mg simvastatin or a combination of 40 mg simvastatin and
10 mg ezetimibe [47]; ezetimibe is a second line lipid-lowering drug that reduces intestinal absorption
of cholesterol and is used as add-on therapy when response to statins is suboptimal or in the event
of statin intolerance. The consistency of results from these studies suggest that despite statin and
other lipid lowering therapies, residual inflammatory risk is common and over twice as prevalent as
residual cholesterol risk. This is not surprising given that statin therapy has only relatively modest
anti-inflammatory effects despite being highly effective in reducing LDL-C levels. Furthermore, results
from IMPROVE-IT show that patients who achieved both a reduction in residual inflammatory risk
and residual cholesterol risk had lower rates of the primary endpoint, defined as a composite of major
coronary event, non-fatal stroke and cardiovascular death, compared to those who achieved reductions
in only one residual risk [46]. Therefore, there is a clear need for future novel therapies to address the
currently unmet issue of residual inflammatory risk in patients found to have persistent inflammation
following standard care.
5. Anti-Cytokine Therapy in Atherosclerosis: The Basis for Human Trials
The role of cytokines in atherosclerosis is complex with new discoveries constantly adding to
our understanding of their function [48]. Cytokines are low-molecular weight proteins produced by
various cell types that serve to mediate host inflammatory responses between cells [49,50]. Since the
first ever description of interleukins in the early 1940s, cytokine classification has expanded to include
over 30 interleukins, as well as branching to include other functional families of cytokines, including
interferons, transforming growth factors and tumor necrosis factors.
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Human data implicating cytokines in the development and progression of atherosclerosis date
back to cohort studies conducted two decades ago, of which the National Institutes of Health-funded
Physicians Health Study [51] and Women’s Health Study [52] are most prominent. These studies found
that elevated levels of circulating cytokines, such as IL-6, as well as elevated adhesion molecules, such as
VCAM-1 and ICAM-1, were predictive of future myocardial infarction and stroke in apparently healthy
individuals [51–54]. These results have subsequently been validated, with a recent meta-analysis
concluding that other pro-inflammatory cytokines, including IL-18, MPP-9 (metalloproteinase-9)
and TNF-α (tumor necrosis factor-alpha) are also associated with increased risk of MACE [55].
The IL-6 signaling pathway has emerged as an especially promising candidate for cytokine-based
therapy, with Mendelian randomisation studies implicating it in both atherogenesis and acute
plaque rupture [56–58]. IL-6 is produced by several cell types including monocytes, fibroblasts
and endothelial cells upon stimulation by IL-1 [59]. IL-1β, the major circulating form of IL-1, is in
turn activated by the NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome.
Inflammasomes are intracellular protein multimer complexes that play critical roles in the production
of pro-inflammatory cytokines. The assembled NLRP3 inflammasome is formed from the combination
of NLRP3, apoptosis-associated speck-like protein (ASC) and caspase-1. This complex activates
procaspase-1 to caspase-1, which in turn converts pro-IL-1β and pro-IL-18 into their bioactive,
pro-atherogenic forms, IL-1β and IL-18. Data linking IL-1β to atherosclerosis stem from early work
demonstrated that a lack of IL-1β decreases the severity of atherosclerosis [60] and that administration
of a monoclonal antibody targeted against IL-1β limits the progression of atherosclerosis in ApoE
deficient mice [61]. Similar results have been reported in preclinical studies involving IL-18 [62,63].
Unlike other markers of inflammation, hsCRP is a validated downstream marker of inflammation
that remains stable over time, has no diurnal variation and captures much of the upstream inflammatory
cascade, including the aforementioned IL-1/IL-6 signaling pathway [64,65]. While initially described
as a component of the acute inflammatory response in 1930, it gained traction among cardiovascular
researchers in the 1990s as studies came to light showing that elevated levels of hsCRP were associated
with acute coronary events, sudden death from cardiac cause and stroke [66–69]. Analysis of data
from the Physician’s Health Study showed that elevated levels of hsCRP were prevalent among
apparently healthy individuals prior to their first cardiovascular event [70]. Furthermore, this study
also highlighted the value of assessing inflammatory state in at-risk patients, with multivariate-adjusted
analyses suggesting that hsCRP was a stronger predictor of a first cardiovascular event than LDL-C
level. The relationship between hsCRP and cardiovascular outcomes was later supported by a
meta-analysis, which involved over 160,000 individuals from 54 long-term prospective studies amassing
nearly 28,000 adverse clinical outcomes [71]. This showed that each standard deviation increase
in log-normalised hsCRP was associated with an increase in relative risk of 1.37 (95% CI 1.27–1.48)
for CAD and 1.55 (95% CI 1.37–1.76) for cardiovascular mortality when adjusted for traditional risk
factors [71].
Taken into context, attempts to reduce inflammatory burden were naturally seen as the next step
in further reducing cardiovascular risk in the “statin era”. Given the growing body of epidemiological
and experimental data over the last two decades implicating inflammatory pathways in atherosclerosis
(Figure 2), studies have now progressed into clinical trials investigating the efficacy of various novel
anti-inflammatory agents in preventing atherosclerotic complications. However, the substantial costs
associated with developing novel pathway specific anti-inflammatory agents represents a major
barrier in translating the preclinical research into a commercial atherosclerosis treatment. Therefore,
the field has also seen efforts to repurpose established agents that have broad, more pleiotropic
anti-inflammatory effects to provide a cost-effective solution to address residual inflammatory risk.
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Figure 2. Inflammatory pathways involved in atherosclerosis. Data from preclinical and clinical
trials suggest an intricate balance between pro-inflammatory and anti-inflammatory pathways. It is
this balance that determines the development and progression of atherosclerotic plaque that may
result in the thrombotic complications associated with plaque rupture. CRP, C-reactive protein;
MMPs, matrix metalloproteinases; IFN-γ, interferon-gamma; IL-1α, interleukin-1-alpha; IL-1β,
interleukin-1-beta; IL-2, interleukin-2; IL-6, interleukin-6; IL-10, interleukin-10; IL-18, interleukin-18;
Lp-PLA2, lipoprotein-associated phospholipase A2; TGF-β, transforming growth factor beta; Th-1,
T-helper-1 lymphocyte; TNF-α, tumor necrosis factor alpha; T-reg, regulatory T lymphocyte.
6. A New Era: Human Trials Targeting Cytokine Inhibition
Early clinical trials of cytokine-targeted therapies for CVD were conducted in the setting
of congestive heart failure, with most large studies failing to demonstrate benefit in mortality
or hospitalisation rates in these patients. These studies primarily involved inhibition of TNF-α
with etanercept [72], a decoy receptor that lowers circulating levels of TNF-α, and infliximab [73],
a monoclonal antibody to TNF-α. Given the lack of benefit in patients with heart failure, as well as
the potential for TNF-α inhibitors to adversely affect lipid profiles, interest in targeting TNF-α in
atherosclerotic CVD has been limited [72–75]. To date, the most successful trials involving anti-cytokine
therapy for atherosclerotic CVD have targeted IL-1β, the major circulating form of IL-1, with subsequent
downstream effects on IL-6 (Table 1). The most prominent of these is the CANTOS (Canakinumab
Anti-inflammatory Thrombosis Outcome Study) trial published in late 2017 [76].
J. Clin. Med. 2019, 8, 1109 8 of 20
Table 1. Major published clinical trials involving anti-inflammatory agents in atherosclerotic
heart disease.
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6.1. Canakinumab: The C NTOS Trial
CANTOS was a randomised, doubl blind, placebo-controlled t i l of 10,061 patients with stable
CAD, who had suffered a previous MI and ha an elevated inflammatory state, defined as hsCRP of
greater than 2 mg/L [76]. To ad re s questions regar i g residual i fla matory risk de pite tandard
care, over 90% of study participants we e on statin therapy, 80% were treated for hypertension and
40% were on treatment for d abetes mellitus. Patients w re assigned t four gr ups that received three
monthly subcutaneous injections f canakinumab, a human monoclonal antibody targeti g IL-1β,
at three different doses (50 mg, 150 mg or 300 mg) or placebo. Canakinumab is currently approved for
rare autoinflammatory syndro es, such as Muckle–Wells syndrom , and as a s cond li e bi logic
agent for rheumatoid iseas s. The dos of canakinumab selecte f r this trial were b sed on a
pilot study involving 566 high risk patients who had wel -controlled di betes mellitus and received
doses ranging from 5 mg to 150 mg [81]. Although o change in LDL-C levels were observed in
this smaller study, can kinumab re uced hsCRP levels by proxi tely 65% with no cl ar dose
response effect [81]. Therefore, the higher a d lower doses anchored around 150 mg used in CANTOS
were selected to address questions relating to safety and dose-response. After 48 months, CANTOS
participants who received 150 m r 300 mg of canakinumab had 35% to 40% r duction in hsCRP
compared to placebo, without significant reductions in LDL-C. A similar magnitude of reduction was
observed in IL-6 levels measured at 12 months.
The primary endpoint of the study was the first occurrence of a MACE, which was defined as a
composite of MI, non-fatal stroke, or card ovascular death. Canakinumab significantly reduce this
J. Clin. Med. 2019, 8, 1109 9 of 20
endpoint to 3.86 events per 100 person-years in the 150 mg group compared to 4.5 per 100 person-years
in the placebo group, translating to a 15% relative risk reduction for MACE (hazard ratio (HR) 0.85,
95% CI 0.74–0.98; p = 0.0208; threshold p-value of 0.0212). While a similar risk reduction was also
observed in the 300 mg dose group, the threshold p-value for significance was not met (HR 0.86;
95% CI 0.75–0.99; p = 0.0314; threshold p-value of 0.0106). No significant benefit when compared to
placebo was achieved in participants receiving 50 mg (HR 0.93; 95% CI 0.80–1.07; p = 0.30; threshold
p-value = 0.0212), suggesting that doses of at least 150 mg are required for meaningful cardiovascular
protection. Subgroup analysis of CANTOS participants showed that those who achieved hsCRP levels
< 2 mg/L on canakinumab, termed “cytokine responders”, had a 25% reduction in MACE (HR 0.75;
95% CI 0.66–0.85; p < 0.0001), whereas cytokine non-responders had no significant benefit (HR 0.90;
95% CI 0.79–1.02; p = 0.11) [82]. Similarly, of n = 4833 participants who had IL-6 levels measured at
baseline, those who achieved on-treatment levels below the study median of 1.65 ng/L had a striking
32% reduction in MACE (HR 0.68; 95% CI 0.56–0.82; p < 0.0001) [83]. Taken together, CANTOS
provides robust evidence that inhibition of pro-inflammatory pathways, at least in the IL-1β/IL-6
signally cascade, can yield significant reduction in cardiovascular risk that is independent of any lipid
lowering effect. Crucially, this benefit applies to individuals who have a clear inflammatory biomarker
response to canakinumab and is incremental to the use of conventional CAD pharmacotherapies.
An important consideration for all trials involving novel pharmacological therapies is adverse
events. In regards to anti-inflammatory agents, the major adverse effect anticipated is reduced host
immunity with subsequent increased rates of infection. In CANTOS, patients receiving canakinumab
had a significantly higher incidence of fatal infection and sepsis compared to placebo (incidence rate
0.31 vs. 0.18 events per 100 person-years; p = 0.02). The majority of these infections were due to
gram positive organisms rather than opportunistic infections or reactivation of tuberculosis. While
these infections can be treated with antibiotics, the results of CANTOS highlight the importance of
vigilant clinical surveillance following the administration of any anti-inflammatory agent. Furthermore,
another concern of anti-inflammatory agents has the potential for cancer given the role the immune
system has in cancer surveillance. In CANTOS, no significant difference in cancer incidence was
observed between patients given canakinumab compared to those given placebo (p = 0.38). Instead,
patients given canakinumab had a significantly lower cancer mortality rate than the placebo group.
This benefit was predominantly due to a reduction in lung cancer rate, specifically non-small cell lung
cancer [84].
Given the positive results of CANTOS with canakinumab, attention has now turned to how to
best reduce residual inflammatory risk in patients with atherosclerotic CAD in real-world practice.
One challenge facing the use of canakinumab is that its high cost makes it unlikely to be adopted for
widespread use given the high prevalence of atherosclerotic CAD [2]. Given the multifarious nature
of inflammation in atherosclerotic processes, an attractive alternative strategy is the repurposing of
established, generic drugs that have broad anti-inflammatory properties for atheroprotection. Two
potential candidates that have been investigated in clinical trials are methotrexate and colchicine.
6.2. Methotrexate: The Cardiovascular Inflammation Reduction Trial (CIRT) Trial
In contrast to CANTOS which employed a relatively narrow-spectrum, pathway-specific approach
to targeting inflammation, CIRT (Cardiovascular Inflammation Reduction Trial) was aimed at
determining whether low dose methotrexate, a broad-spectrum anti-inflammatory drug, could
also achieve reductions in cardiovascular events [77]. Methotrexate is an established, inexpensive drug
with pleiotropic upstream anti-inflammatory activity that is used as first line therapy for conditions
characterised by systemic inflammation, such as rheumatoid arthritis and psoriasis. In contrast to high
dose methotrexate which acts via an anti-proliferative cytotoxic mechanism, low dose methotrexate
regulates inflammation through the inhibition of aminoimidazole-4-carboximide ribonucleotide
(AICAR), which results in increased levels of adenosine. This in turn is thought to down-regulate
inflammation through several mechanisms including the suppression of proinflammatory cytokines
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such as IL-12, IL-6 and TNF-α, upregulating the production of anti-inflammatory cytokines such as
IL-10 and IL-1 receptor antagonist, and down-regulating macrophage activation and the T-helper-1
response [85,86]. The CIRT trial was designed on a background of several observational studies
showing that methotrexate used for rheumatoid conditions was associated with lower CVD risk [87–89],
including a meta-analysis [90] that had found a 21% lower risk for total CVD and 18% lower risk of
MI specifically.
CIRT randomised 4786 participants with a history of previous MI and either type 2 diabetes or
metabolic syndrome to methotrexate at a target oral weekly dose of 15 to 20 mg or placebo. Similar
to CANTOS, both study groups also received standard care, with over 85% of participants on statin
therapy. After a median follow-up of 2.3 years, low dose methotrexate did not significantly reduce IL-1β,
IL-6 or hsCRP levels compared to placebo. Furthermore it did not significantly impact the primary
endpoint of the first occurrence of MACE, defined as a composite of non-fatal MI, non-fatal stroke and
cardiovascular death (HR 1.01; 95% CI 0.82–1.25; p = 0.91), nor the secondary composite endpoint that
comprised MACE and unstable angina presentations requiring unplanned revascularisation (HR 0.96;
95% CI 0.79–1.15; p = 0.67).
In trying to account for the discrepant results between CIRT and CANTOS, two key differences
between these studies warrant specific mention. Firstly, an elevated hsCRP level was not an inclusion
criterion in CIRT participants in contrast to CANTOS. The median baseline hsCRP was 1.5 mg/L in
CIRT compared to 4.2 mg/L in CANTOS. This difference provides an important insight suggesting
that attempts to mitigate cardiovascular risk with anti-inflammatory therapies may only be effective
in patients with atherosclerosis who have an elevated inflammatory signal and therefore residual
inflammatory risk, despite standard care. Secondly, CANTOS which used canakinumab to specifically
target IL-1β reported a significant decrease in IL-1β, IL-6 and hsCRP levels. Low dose methotrexate,
on the other hand, showed no effect on biomarkers of the IL-1β signaling pathway and failed to reduce
hsCRP, a downstream non-specific marker of inflammatory state. This suggests that this treatment
approach had minimal effect, if any, on the IL-1β/IL-6 signaling pathway. The neutral results from CIRT
are consistent with previous clinical trials that also failed to show benefit from other anti-inflammatory
approaches to treating atherosclerosis. These include studies of losmapimod [80], a p38 MAP
(mitogen-activated protein) kinase inhibitor, and darapladib [79], an inhibitor of lipoprotein-associated
phospholipase A2 (Lp-PLA2). Elevated levels of Lp-PLA2 and p38 MAP kinase-mediated immune
activation have been hypothesised to be involved in the pathogenesis of atherosclerosis [91]. Therefore,
not all therapies with putative anti-inflammatory effects are capable of achieving clinically significant
outcomes in patients with CAD, with the CANTOS results highlighting that the IL-1β/IL-6 pathway is
an especially promising target.
6.3. Alternative Targets in the IL-1β/IL-6 Signaling Pathway
The encouraging results of CANTOS, which identified IL-1β as an effective target for mitigating
residual inflammatory risk, represent a major stimulant to an already nascent field. It is therefore not
surprising that attention has moved up the cytokine stream to target inflammasomes of which NLRP3, a
known activator of IL-1β, is best characterised [92]. The various mechanisms leading to inflammasome
activation and assembly are still an area of ongoing research with numerous pathways identified to
date (Figure 3), one of which has been shown to occur following the exposure of neutrophils and
macrophages to cholesterol crystals in atherosclerotic plaque [93,94]. OxLDL and other types of
crystals, including uric acid crystals as seen in gout, are also known to activate the pro-inflammatory
NLRP3 response [93,95]. Alone, these activators are unable to initiate the assembly of the NLRP3
inflammasome unless an initial priming step occurs [96]. This is thought to be due to low protein levels
of NLRP3 in unprimed macrophages. Priming of macrophages is mediated by NF-κB signaling with the
stimulus provided by endogenous cytokines, such as IL-1 and TNF-α, as well as pathogen-associated
molecular patterns (PAMPs) on microbial molecules that interact with toll-like receptors (TLR). This in
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turn upregulates the expression of NLRP3 and pro-IL-1β thus providing the reactants required for
NLRP3 inflammasome formation and function (Figure 3) [97].
Figure 3. Two signal activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3)
inflammasome. Activation of the NLRP3 inflammasome requires both the initial priming step (left)
following by the activation step (right). Priming of macrophages is provided by endogenous cytokines
(IL-1 and TNF-α) and binding of PAMPs on microbial molecules to membrane-bound TLR. The second
activation step involves a variety of stimuli, including intracellular oxLDL accumulation, PAMPs, and
crystalloid particulates such as uric and cholesterol crystals. The NLRP3 inflammasome catalyses
the conversion of pro-caspase-1 to its active form, caspase-1, which then converts pro-IL-1β and
pro-IL-18 into their bioactive, pro-atherogenic forms, IL-1β and IL-18. ASC, apoptosis-associated
speck-like protein; IL-1, interleukin 1; IL-1R, interleukin-1 receptor; NLRP3, NOD-like receptor family
pyrin domain containing 3; oxLDL, oxidised low-density lipoproteins; PAMPs, pathogen-associated
molecular patterns; ROS, reactive oxygen species; TLR, toll-like receptors; TNF-α, tumor necrosis factor
alpha; TNFR, tumor necrosis factor receptors.
To date, animal studies utilising NLRP3 inhibitors in cardiovascular disease models have shown
encouraging results [98,99]. One such study showed significant reductions in the development of
atherosclerotic lesion size as well as VCAM-1 and ICAM-1 mRNA expression in hyperlipidaemic
mice when given MCC950, a selective NLRP3 inhibitor, compared to controls [99]. While macrophage
infiltration of plaque was found to be reduced, possibly due to reduced monocyte adhesion via VCAM-1
and ICAM-1 downregulation, further research is required to fully elicit the mechanisms underlying
these findings. Reduction in infarct size and preservation of left ventricular ejection fraction have also
been reported for MCC950 in a pig model of MI [98].
Inhibition of IL-6, which is downstream of IL-1β, is also seen as a potential target for anti-inflammatory
intervention. Early experimental data implicating IL-6 in atherosclerosis demonstrated that exogenous
injection of IL-6 into hyperlipidaemic mice significantly increased atherosclerotic lesion size [100].
Subsequently, recent data have shown that administration of MR16-1, a murine IL-6 receptor antibody,
yields significant atheroprotection in hyperlipidaemic mice [101]. Therefore, agents that target IL-6
binding, such as tocilizumab, or alter IL-6 receptor activity, such as sarilumab, warrant investigation for
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atheroprotective benefits in patients with atherosclerosis. Promising results from a small randomised
trial showed that a single dose of tocilizumab reduced troponin levels in patients presenting with acute
coronary syndrome, suggesting a possible reduction in infarct size [102]. However, while tocilizumab
is currently used clinically in patients with rheumatoid arthritis, it has been associated with increasing
LDL-C and weight gain [103,104], which in theory could promote atherosclerosis and potentially
negate any long-term benefit gained from its anti-inflammatory actions.
6.4. Colchicine: The LoDoCo Trial
Another emerging candidate for repurposing in atherosclerosis is colchicine, an anti-inflammatory
drug used to treat gout and other inflammatory disorders, such as familial Mediterranean fever
(FMF) and recurrent pericarditis. Colchicine binds to microtubule ends and inhibits cytoskeletal
microtubule processes [105]. Therefore, it affects several microtubule-dependent processes such
as neutrophil chemotaxis, phagocytosis and protein excretion. It has also been shown to limit the
expression of adhesion molecules on the surface of leukocytes and endothelial cells [106]. Furthermore,
a recent advance has been the discovery of attenuated activation of the NLRP3 inflammasome in
colchicine-treated neutrophils and macrophages in response to monosodium urate crystals in the
setting of gout [95,105]. This has led to speculation that colchicine can also mitigate cholesterol
crystal-induced inflammation via NLRP3 attenuation within atherosclerotic plaque.
Since Food and Drug Administration (FDA) approval in 2009 for use in gout and FMF, numerous
studies have reported that colchicine may be beneficial in different cardiovascular disease states [107].
This is consistent with retrospective observations that found a lower rate of MI in patients with gout
and FMF who are treated with colchicine [108,109]. Building upon this growing body of evidence,
the LoDoCo (Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease) study was a
placebo-controlled, observer-blinded trial that randomised 532 patients with stable atherosclerosis
to receive either 0.5 mg/day of colchicine or placebo in addition to standard care [78]. After a
median follow-up of 3 years, participants who were given colchicine had a marked reduction in a
composite endpoint consisting of MI, cardiac arrest or non-cardioembolic stroke compared to placebo
(HR 0.33; 95% CI 0.18–0.59; p < 0.001). Although the mechanism of benefit of colchicine was not
investigated in this trial, colchicine has been shown to acutely lower the local production of NLRP3
inflammasome-related cytokines, IL-1β, IL-18 and IL-6, in the coronary vascular bed of patients with
acute coronary syndrome [110]. Furthermore, a recent study using coronary computed tomography
(CT) angiography found that regular colchicine use at a dose of 0.5 mg/day favourably modified the
composition of coronary atherosclerotic lesions by reducing low attenuation plaque volume, a known
predictor of future MACE [111]. Finally, similar to canakinumab and in contrast to methotrexate,
colchicine has been shown to lower hsCRP by more than 50% in patients who have stable CAD with
elevated levels of inflammation (hsCRP ≥ 2 mg/L), incrementally to statin therapy [112]. These results
have sparked five registered clinical trials (Table 2) of colchicine that are currently recruiting patients
with stable CAD (LoDoCo II), unstable CAD (Colchicine Cardiovascular Outcomes Trial (COLCOT),
Colchicine for Acute Coronary Syndromes (COACS), Colchicine and Spironolactone in Patients with
STEMI/SYNERGY Stent Registry (CLEAR-SYNERGY)) and cerebrovascular disease (CONVINCE).
Repurposing of colchicine for use in atherosclerosis is not without its own challenges given
its well-known propensity to cause gastrointestinal side-effects in up to 25% of patients [113,114].
Therefore, definitive proof of efficacy, as well as further mechanistic understanding of how colchicine
attenuates cardiovascular risk in CAD will facilitate physician confidence in prescribing this drug, as
was the case with statins during their early development.
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Table 2. Ongoing clinical studies involving colchicine in cardiovascular disease.
Trial Name PrimarySite(s) Study Design
Patient
Number Intervention Primary Outcomes Follow-up
Completion
Date
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5 years 21 Oct
Abbreviations: ACS, acute coronary syndrome; MI, myocardial infarction.
7. Clonal Haematopoiesis: A Novel Risk Factor for Atherosclerosis
Clonal haematopoiesis of indeterminant potential (CHIP) occurs with normal ageing and is the
result of accumulated somatic mutations in bone marrow stem cells [115,116]. These somatic mutations
provide selective advantages over unaffected stem cells resulting in an increased relative proportion
of these clones in the peripheral circulation without causing any other haematological abnormalities.
The most common genes affected by mutations in CHIP, in order of decreasing frequency, are the
epigenetic regulars DNMT3A (DNA methyltransferase 3 alpha), TET2 (Tet methylcytosine dioxygenase
2) and ASXL1 (additional sex combs like 1). Results from cohort studies confirm that CHIP is an
age-related disorder affecting up to 16.4% of people aged over 80, compared to less than 1% of those
under the age of 40 [115]. While CHIP conveys an increased risk of haematological malignancy (HR
11.1; 95% CI 3.9–32.6), carriers of its associated mutations are also 1.9 times more likely than non-carriers
to have CAD (95% CI 1.4–2.7) and 4 times more likely to have an MI (95% CI 2.4–6.7) [117]. Therefore,
CVD may account for a disproportionate number of non-haematological mortalities in CHIP carriers.
Attempts to investigate CHIP in preclinical studies have shown promising results that link its
associated mutations to the development of atherosclerosis. Atherosclerosis-prone mice transplanted
with TET2-deficient haematopoietic stem cells developed larger atherosclerotic lesions than controls
without significant differences in lipid levels [117]. Analysis of macrophages extracted from these
TET2-deficient mice showed increased levels of pro-inflammatory cytokines, including IL-1β and
IL-6. Furthermore, in a murine model of heart failure, TET2 deficiency-associated cardiac dysfunction
was associated with a corresponding increase in IL-1β levels. Interestingly, in this study treatment
with MCC950, a selective NLRP3 inhibitor, protected against the development of heart failure in
TET2-deficient mice [118]. Therefore, further research on CHIP and its associated mutations may provide
yet another target for future therapeutic agents to attenuate the associated increased cardiovascular risk.
8. Conclusions
Positive lifestyle interventions, such as weight control, smoking cessation and physical exercise,
remain the basis of primary prevention of CVD and should accompany any pharmacological therapy
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aimed at addressing cardiovascular risk. Despite this, cardiovascular events continue to occur at
alarming rates with residual inflammation recently identified as a treatable pathogenic factor. Results
from the CANTOS trial establish that inflammation, specifically via the IL-1β/IL-6 signally pathway,
is a therapeutic target capable of achieving clinically significant benefits in those shown to have residual
inflammation despite contemporary standard care. With numerous clinical trials investigating other
anti-inflammatory agents underway, it is clear that CANTOS represents only the beginning of what
promises to be an exciting and rapidly moving era of research in atherosclerotic CVD. The recent
discovery of CHIP as another novel risk factor for CVD further highlights the existence of atherogenic
pathways that are independent of traditional risk factors. With inflammation now clearly shown to be
an important mediator and risk factor in atherosclerosis, it is these previously unsuspected pathways
that may serve as the future frontier for cardiovascular risk modification.
Author Contributions: M.T.N and P.J.P.: manuscript conception, research, planning, writing. S.F., N.S., J.T.M.T.,
C.A.B: intellectual input, edited manuscript, proof-reading.
Funding: This manuscript was supported by a project grant from the National Health and Medical Research
Council of Australia (GNT1127159, P.J.P.). P.J.P. receives fellowship funding from the National Heart Foundation of
Australia (Future Leader Fellowship FLF102056) and National Health and Medical Research Council of Australia
(CDF1161506).
Conflicts of Interest: P.J.P. has received research support from Abbott Vascular, consultancy fees from ESPERION
and AMGEN, and speaker honoraria from AstraZeneca, Merck, Pfizer and Bayer.
References
1. Benjamin, E.J.; Muntner, P.; Alonso, A.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.;
Chang, A.R.; Cheng, S.; Das, S.R.; et al. Heart disease and stroke statistics-2019 update: A report from the
american heart association. Circulation 2019, 139, e56–e528. [CrossRef]
2. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis.
Nature 2011, 473, 317–325. [CrossRef]
3. Collins, R.; Reith, C.; Emberson, J.; Armitage, J.; Baigent, C.; Blackwell, L.; Blumenthal, R.; Danesh, J.;
Smith, G.D.; DeMets, D.; et al. Interpretation of the evidence for the efficacy and safety of statin therapy.
Lancet (Lond. Engl.) 2016, 388, 2532–2561. [CrossRef]
4. Jernberg, T.; Hasvold, P.; Henriksson, M.; Hjelm, H.; Thuresson, M.; Janzon, M. Cardiovascular risk in
post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a long-term
perspective. Eur. Heart J. 2015, 36, 1163–1170. [CrossRef]
5. Libby, P.; Loscalzo, J.; Ridker, P.M.; Farkouh, M.E.; Hsue, P.Y.; Fuster, V.; Hasan, A.A.; Amar, S. Inflammation,
immunity, and infection in atherothrombosis: Jacc review topic of the week. J. Am. Coll. Cardiol. 2018, 72,
2071–2081. [CrossRef]
6. Hwang, S.J.; Ballantyne, C.M.; Sharrett, A.R.; Smith, L.C.; Davis, C.E.; Gotto, A.M., Jr.; Boerwinkle, E.
Circulating adhesion molecules vcam-1, icam-1, and e-selectin in carotid atherosclerosis and incident
coronary heart disease cases: The atherosclerosis risk in communities (aric) study. Circulation 1997, 96,
4219–4225. [CrossRef]
7. Ridker, P.M.; Buring, J.E.; Rifai, N. Soluble p-selectin and the risk of future cardiovascular events. Circulation
2001, 103, 491–495. [CrossRef]
8. Cybulsky, M.I.; Iiyama, K.; Li, H.; Zhu, S.; Chen, M.; Iiyama, M.; Davis, V.; Gutierrez-Ramos, J.C.;
Connelly, P.W.; Milstone, D.S. A major role for vcam-1, but not icam-1, in early atherosclerosis. J. Clin.
Investig. 2001, 107, 1255–1262. [CrossRef]
9. Nageh, M.F.; Sandberg, E.T.; Marotti, K.R.; Lin, A.H.; Melchior, E.P.; Bullard, D.C.; Beaudet, A.L. Deficiency of
inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol.
1997, 17, 1517–1520. [CrossRef]
10. Dong, Z.M.; Brown, A.A.; Wagner, D.D. Prominent role of p-selectin in the development of advanced
atherosclerosis in apoe-deficient mice. Circulation 2000, 101, 2290–2295. [CrossRef]
J. Clin. Med. 2019, 8, 1109 15 of 20
11. Collins, R.G.; Velji, R.; Guevara, N.V.; Hicks, M.J.; Chan, L.; Beaudet, A.L. P-selectin or intercellular adhesion
molecule (icam)-1 deficiency substantially protects against atherosclerosis in apolipoprotein e-deficient mice.
J. Exp. Med. 2000, 191, 189–194. [CrossRef]
12. McGill, H.C., Jr.; McMahan, C.A.; Herderick, E.E.; Malcom, G.T.; Tracy, R.E.; Strong, J.P. Origin of
atherosclerosis in childhood and adolescence. Am. J. Clin. Nutr. 2000, 72, 1307s–1315s.
13. Strong, J.P.; Malcom, G.T.; Newman, W.P., 3rd; Oalmann, M.C. Early lesions of atherosclerosis in childhood
and youth: Natural history and risk factors. J. Am. Coll. Nutr. 1992, 11 (Suppl. 1), 51s–54s. [CrossRef]
14. Chistiakov, D.A.; Bobryshev, Y.V.; Orekhov, A.N. Macrophage-mediated cholesterol handling in
atherosclerosis. J. Cell. Mol. Med. 2016, 20, 17–28. [CrossRef]
15. Ohashi, R.; Mu, H.; Wang, X.; Yao, Q.; Chen, C. Reverse cholesterol transport and cholesterol efflux in
atherosclerosis. QJM Mon. J. Assoc. Physicians 2005, 98, 845–856. [CrossRef]
16. Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol.
2010, 10, 36–46. [CrossRef]
17. Nadkarni, S.K.; Bouma, B.E.; de Boer, J.; Tearney, G.J. Evaluation of collagen in atherosclerotic plaques:
The use of two coherent laser-based imaging methods. Lasers Med Sci. 2009, 24, 439–445. [CrossRef]
18. Alexander, M.R.; Owens, G.K. Epigenetic control of smooth muscle cell differentiation and phenotypic
switching in vascular development and disease. Annu. Rev. Physiol. 2012, 74, 13–40. [CrossRef]
19. Hansson, G.K.; Jonasson, L. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler.
Thromb. Vasc. Biol. 2009, 29, 1714–1717. [CrossRef]
20. Wu, M.Y.; Li, C.J.; Hou, M.F.; Chu, P.Y. New insights into the role of inflammation in the pathogenesis of
atherosclerosis. Int. J. Mol. Sci. 2017, 18, 2034. [CrossRef]
21. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352,
1685–1695. [CrossRef]
22. Witztum, J.L.; Binder, C.J.; Chou, M.-Y.; Fogelstrand, L.; Hartvigsen, K.; Shaw, P.X.; Boullier, A. Natural
antibodies in murine atherosclerosis. Curr. Drug Targets 2008, 9, 190–195. [CrossRef]
23. Caligiuri, G.; Nicoletti, A.; Poirier, B.; Hansson, G.K. Protective immunity against atherosclerosis carried by b
cells of hypercholesterolemic mice. J. Clin. Investig. 2002, 109, 745–753. [CrossRef]
24. Shaw, P.X.; Horkko, S.; Chang, M.K.; Curtiss, L.K.; Palinski, W.; Silverman, G.J.; Witztum, J.L. Natural
antibodies with the t15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity.
J. Clin. Investig. 2000, 105, 1731–1740. [CrossRef]
25. Kyaw, T.; Tipping, P.; Bobik, A.; Toh, B.H. Opposing roles of b lymphocyte subsets in atherosclerosis.
Autoimmunity 2017, 50, 52–56. [CrossRef]
26. Tedgui, A.; Mallat, Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol. Rev. 2006,
86, 515–581. [CrossRef]
27. Turesson, C.; Jacobsson, L.T.H.; Matteson, E.L. Cardiovascular co-morbidity in rheumatic diseases. Vasc. Health
Risk Manag. 2008, 4, 605–614. [CrossRef]
28. Woolf, A.D.; Pfleger, B. Burden of major musculoskeletal conditions. Bull. World Health Organ. 2003, 81,
646–656.
29. England, B.R.; Thiele, G.M.; Anderson, D.R.; Mikuls, T.R. Increased cardiovascular risk in rheumatoid
arthritis: Mechanisms and implications. BMJ 2018, 361, k1036. [CrossRef]
30. Widdifield, J.; Paterson, J.M.; Huang, A.; Bernatsky, S. Causes of death in rheumatoid arthritis: How do they
compare to the general population? Arthritis Care Res. 2018, 70, 1748–1755. [CrossRef]
31. Avina-Zubieta, J.A.; Thomas, J.; Sadatsafavi, M.; Lehman, A.J.; Lacaille, D. Risk of incident cardiovascular
events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann. Rheum. Dis.
2012, 71, 1524–1529. [CrossRef]
32. Avina-Zubieta, J.A.; Choi, H.K.; Sadatsafavi, M.; Etminan, M.; Esdaile, J.M.; Lacaille, D. Risk of cardiovascular
mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Rheum.
2008, 59, 1690–1697. [CrossRef]
33. Peters, M.J.; van Halm, V.P.; Voskuyl, A.E.; Smulders, Y.M.; Boers, M.; Lems, W.F.; Visser, M.; Stehouwer, C.D.;
Dekker, J.M.; Nijpels, G.; et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk
factor for cardiovascular disease? A prospective study. Arthritis Rheum. 2009, 61, 1571–1579. [CrossRef]
J. Clin. Med. 2019, 8, 1109 16 of 20
34. Pujades-Rodriguez, M.; Duyx, B.; Thomas, S.L.; Stogiannis, D.; Rahman, A.; Smeeth, L.; Hemingway, H.
Rheumatoid arthritis and incidence of twelve initial presentations of cardiovascular disease: A population
record-linkage cohort study in england. PLoS ONE 2016, 11, e0151245. [CrossRef]
35. Del Rincon, I.D.; Williams, K.; Stern, M.P.; Freeman, G.L.; Escalante, A. High incidence of cardiovascular
events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum.
2001, 44, 2737–2745. [CrossRef]
36. Gonzalez-Gay, M.A.; Gonzalez-Juanatey, C.; Lopez-Diaz, M.J.; Pineiro, A.; Garcia-Porrua, C.;
Miranda-Filloy, J.A.; Ollier, W.E.; Martin, J.; Llorca, J. Hla-drb1 and persistent chronic inflammation
contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis.
Arthritis Rheum. 2007, 57, 125–132. [CrossRef]
37. Sattar, N.; McInnes, I.B. Vascular comorbidity in rheumatoid arthritis: Potential mechanisms and solutions.
Curr. Opin. Rheumatol. 2005, 17, 286–292. [CrossRef]
38. Dregan, A.; Charlton, J.; Chowienczyk, P.; Gulliford, M.C. Chronic inflammatory disorders and risk of type 2
diabetes mellitus, coronary heart disease, and stroke: A population-based cohort study. Circulation 2014, 130,
837–844. [CrossRef]
39. Mason, J.C.; Libby, P. Cardiovascular disease in patients with chronic inflammation: Mechanisms underlying
premature cardiovascular events in rheumatologic conditions. Eur. Heart J. 2015, 36, 482–489. [CrossRef]
40. Teague, H.; Mehta, N.N. The link between inflammatory disorders and coronary heart disease: A look at
recent studies and novel drugs in development. Curr. Atheroscler. Rep. 2016, 18, 3. [CrossRef]
41. Armstrong, A.W.; Voyles, S.V.; Armstrong, E.J.; Fuller, E.N.; Rutledge, J.C. A tale of two plaques: Convergent
mechanisms of t-cell-mediated inflammation in psoriasis and atherosclerosis. Exp. Dermatol. 2011, 20,
544–549. [CrossRef]
42. Matsuura, E.; Atzeni, F.; Sarzi-Puttini, P.; Turiel, M.; Lopez, L.R.; Nurmohamed, M.T. Is atherosclerosis an
autoimmune disease? BMC Med. 2014, 12, 47. [CrossRef]
43. Ridker, P.M.; Danielson, E.; Fonseca, F.A.H.; Genest, J.; Gotto, A.M.; Kastelein, J.J.P.; Koenig, W.; Libby, P.;
Lorenzatti, A.J.; MacFadyen, J.G.; et al. Rosuvastatin to prevent vascular events in men and women with
elevated c-reactive protein. N. Engl. J. Med. 2008, 359, 2195–2207. [CrossRef]
44. Cannon, C.P.; Braunwald, E.; McCabe, C.H.; Rader, D.J.; Rouleau, J.L.; Belder, R.; Joyal, S.V.; Hill, K.A.;
Pfeffer, M.A.; Skene, A.M. Intensive versus moderate lipid lowering with statins after acute coronary
syndromes. N. Engl. J. Med. 2004, 350, 1495–1504. [CrossRef]
45. Ridker, P.M.; Cannon, C.P.; Morrow, D.; Rifai, N.; Rose, L.M.; McCabe, C.H.; Pfeffer, M.A.; Braunwald, E.
C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 2005, 352, 20–28. [CrossRef]
46. Bohula, E.A.; Giugliano, R.P.; Cannon, C.P.; Zhou, J.; Murphy, S.A.; White, J.A.; Tershakovec, A.M.;
Blazing, M.A.; Braunwald, E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity
c-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with
better outcomes in improve-it. Circulation 2015, 132, 1224–1233. [CrossRef]
47. Cannon, C.P.; Blazing, M.A.; Giugliano, R.P.; McCagg, A.; White, J.A.; Theroux, P.; Darius, H.; Lewis, B.S.;
Ophuis, T.O.; Jukema, J.W.; et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl.
J. Med. 2015, 372, 2387–2397. [CrossRef]
48. Tousoulis, D.; Oikonomou, E.; Economou, E.K.; Crea, F.; Kaski, J.C. Inflammatory cytokines in atherosclerosis:
Current therapeutic approaches. Eur. Heart J. 2016, 37, 1723–1732. [CrossRef]
49. Dinarello, C.A. Historical insights into cytokines. Eur. J. Immunol. 2007, 37 (Suppl. 1), S34–S45. [CrossRef]
50. Dinarello, C.A. Anti-inflammatory agents: Present and future. Cell 2010, 140, 935–950. [CrossRef]
51. Ridker, P.M.; Cushman, M.; Stampfer, M.J.; Tracy, R.P.; Hennekens, C.H. Inflammation, aspirin, and the risk
of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997, 336, 973–979. [CrossRef]
52. Ridker, P.M.; Hennekens, C.H.; Buring, J.E.; Rifai, N. C-reactive protein and other markers of inflammation
in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000, 342, 836–843. [CrossRef]
53. Ridker, P.M.; Hennekens, C.H.; Roitman-Johnson, B.; Stampfer, M.J.; Allen, J. Plasma concentration of soluble
intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet
(Lond. Engl.) 1998, 351, 88–92. [CrossRef]
54. Ridker, P.M.; Rifai, N.; Stampfer, M.J.; Hennekens, C.H. Plasma concentration of interleukin-6 and the risk of
future myocardial infarction among apparently healthy men. Circulation 2000, 101, 1767–1772. [CrossRef]
J. Clin. Med. 2019, 8, 1109 17 of 20
55. Kaptoge, S.; Seshasai, S.R.; Gao, P.; Freitag, D.F.; Butterworth, A.S.; Borglykke, A.; Di Angelantonio, E.;
Gudnason, V.; Rumley, A.; Lowe, G.D.; et al. Inflammatory cytokines and risk of coronary heart disease:
New prospective study and updated meta-analysis. Eur. Heart J. 2014, 35, 578–589. [CrossRef]
56. Swerdlow, D.I.; Holmes, M.V.; Kuchenbaecker, K.B.; Engmann, J.E.; Shah, T.; Sofat, R.; Guo, Y.; Chung, C.;
Peasey, A.; Pfister, R.; et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: A
mendelian randomisation analysis. Lancet (Lond. Engl.) 2012, 379, 1214–1224.
57. Danesh, J.; Kaptoge, S.; Mann, A.G.; Sarwar, N.; Wood, A.; Angleman, S.B.; Wensley, F.; Higgins, J.P.;
Lennon, L.; Eiriksdottir, G.; et al. Long-term interleukin-6 levels and subsequent risk of coronary heart
disease: Two new prospective studies and a systematic review. PLoS Med. 2008, 5, e78. [CrossRef]
58. Sarwar, N.; Butterworth, A.S.; Freitag, D.F.; Gregson, J.; Willeit, P.; Gorman, D.N.; Gao, P.; Saleheen, D.;
Rendon, A.; Nelson, C.P.; et al. Interleukin-6 receptor pathways in coronary heart disease: A collaborative
meta-analysis of 82 studies. Lancet (Lond. Engl.) 2012, 379, 1205–1213.
59. Tosato, G.; Jones, K.D. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood
1990, 75, 1305–1310.
60. Kirii, H.; Niwa, T.; Yamada, Y.; Wada, H.; Saito, K.; Iwakura, Y.; Asano, M.; Moriwaki, H.; Seishima, M. Lack
of interleukin-1beta decreases the severity of atherosclerosis in apoe-deficient mice. Arterioscler. Thromb.
Vasc. Biol. 2003, 23, 656–660. [CrossRef]
61. Bhaskar, V.; Yin, J.; Mirza, A.M.; Phan, D.; Vanegas, S.; Issafras, H.; Michelson, K.; Hunter, J.J.; Kantak, S.S.
Monoclonal antibodies targeting il-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit
atherosclerotic plaque formation in apolipoprotein e-deficient mice. Atherosclerosis 2011, 216, 313–320.
[CrossRef]
62. Elhage, R.; Jawien, J.; Rudling, M.; Ljunggren, H.-G.; Takeda, K.; Akira, S.; Bayard, F.; Hansson, G.K. Reduced
atherosclerosis in interleukin-18 deficient apolipoprotein e-knockout mice. Cardiovasc. Res. 2003, 59, 234–240.
[CrossRef]
63. Mallat, Z.; Corbaz, A.; Scoazec, A.; Graber, P.; Alouani, S.; Esposito, B.; Humbert, Y.; Chvatchko, Y.; Tedgui, A.
Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and
stability. Circ. Res. 2001, 89, e41–e45. [CrossRef]
64. Ockene, I.S.; Matthews, C.E.; Rifai, N.; Ridker, P.M.; Reed, G.; Stanek, E. Variability and classification accuracy
of serial high-sensitivity c-reactive protein measurements in healthy adults. Clin. Chem. 2001, 47, 444–450.
65. Meier-Ewert, H.K.; Ridker, P.M.; Rifai, N.; Price, N.; Dinges, D.F.; Mullington, J.M. Absence of diurnal
variation of c-reactive protein concentrations in healthy human subjects. Clin. Chem. 2001, 47, 426–430.
66. Berk, B.C.; Weintraub, W.S.; Alexander, R.W. Elevation of c-reactive protein in “active” coronary artery
disease. Am. J. Cardiol. 1990, 65, 168–172. [CrossRef]
67. Ablij, H.; Meinders, A. C-reactive protein: History and revival. Eur. J. Intern. Med. 2002, 13, 412–422.
[CrossRef]
68. Albert, C.M.; Ma, J.; Rifai, N.; Stampfer, M.J.; Ridker, P.M. Prospective study of c-reactive protein,
homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002, 105,
2595–2599. [CrossRef]
69. Rost, N.S.; Wolf, P.A.; Kase, C.S.; Kelly-Hayes, M.; Silbershatz, H.; Massaro, J.M.; D’Agostino, R.B.;
Franzblau, C.; Wilson, P.W. Plasma concentration of c-reactive protein and risk of ischemic stroke and
transient ischemic attack: The framingham study. Stroke 2001, 32, 2575–2579. [CrossRef]
70. Ridker, P.M.; Rifai, N.; Rose, L.; Buring, J.E.; Cook, N.R. Comparison of c-reactive protein and low-density
lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002, 347,
1557–1565. [CrossRef]
71. Kaptoge, S.; Di Angelantonio, E.; Lowe, G.; Pepys, M.B.; Thompson, S.G.; Collins, R.; Danesh, J. C-reactive
protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant
meta-analysis. Lancet (Lond. Engl.) 2010, 375, 132–140.
72. Mann, D.L.; McMurray, J.J.; Packer, M.; Swedberg, K.; Borer, J.S.; Colucci, W.S.; Djian, J.; Drexler, H.;
Feldman, A.; Kober, L.; et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of
the randomized etanercept worldwide evaluation (renewal). Circulation 2004, 109, 1594–1602. [CrossRef]
J. Clin. Med. 2019, 8, 1109 18 of 20
73. Chung, E.S.; Packer, M.; Lo, K.H.; Fasanmade, A.A.; Willerson, J.T. Randomized, double-blind,
placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha,
in patients with moderate-to-severe heart failure: Results of the anti-tnf therapy against congestive heart
failure (attach) trial. Circulation 2003, 107, 3133–3140.
74. Hassan, S.; Milman, U.; Feld, J.; Eder, L.; Lavi, I.; Cohen, S.; Zisman, D. Effects of anti-tnf-α treatment on
lipid profile in rheumatic diseases: An analytical cohort study. Arthritis Res. Ther. 2016, 18, 261. [CrossRef]
75. Curtis, J.R.; John, A.; Baser, O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis
and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res. 2012, 64, 1282–1291. [CrossRef]
76. Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.;
Koenig, W.; Anker, S.D.; et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease.
N. Engl. J. Med. 2017, 377, 1119–1131. [CrossRef]
77. Ridker, P.M.; Everett, B.M.; Pradhan, A.; MacFadyen, J.G.; Solomon, D.H.; Zaharris, E.; Mam, V.; Hasan, A.;
Rosenberg, Y.; Iturriaga, E.; et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl.
J. Med. 2019, 380, 752–762. [CrossRef]
78. Nidorf, S.M.; Eikelboom, J.W.; Budgeon, C.A.; Thompson, P.L. Low-dose colchicine for secondary prevention
of cardiovascular disease. J. Am. Coll. Cardiol. 2013, 61, 404–410. [CrossRef]
79. O’Donoghue, M.L.; Braunwald, E.; White, H.D.; Steen, D.L.; Lukas, M.A.; Tarka, E.; Steg, P.G.; Hochman, J.S.;
Bode, C.; Maggioni, A.P.; et al. Effect of darapladib on major coronary events after an acute coronary syndrome:
The solid-timi 52 randomized clinical trialdarapladib and major coronary events after acsdarapladib and
major coronary events after acs. JAMA 2014, 312, 1006–1015. [CrossRef]
80. O’Donoghue, M.L.; Glaser, R.; Cavender, M.A.; Aylward, P.E.; Bonaca, M.P.; Budaj, A.; Davies, R.Y.;
Dellborg, M.; Fox, K.A.A.; Gutierrez, J.A.T.; et al. Effect of losmapimod on cardiovascular outcomes in
patients hospitalized with acute myocardial infarction: A randomized clinical trialeffect of losmapimod
on cardiovascular outcomes in patients with acute mieffect of losmapimod on cardiovascular outcomes in
patients with acute mi. JAMA 2016, 315, 1591–1599.
81. Ridker, P.M.; Howard, C.P.; Walter, V.; Everett, B.; Libby, P.; Hensen, J.; Thuren, T. Effects of interleukin-1beta
inhibition with canakinumab on hemoglobin a1c, lipids, c-reactive protein, interleukin-6, and fibrinogen:
A phase iib randomized, placebo-controlled trial. Circulation 2012, 126, 2739–2748. [CrossRef]
82. Ridker, P.M.; MacFadyen, J.G.; Everett, B.M.; Libby, P.; Thuren, T.; Glynn, R.J. Relationship of c-reactive
protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary
analysis from the cantos randomised controlled trial. Lancet (Lond. Engl.) 2018, 391, 319–328. [CrossRef]
83. Ridker, P.M.; Libby, P.; MacFadyen, J.G.; Thuren, T.; Ballantyne, C.; Fonseca, F.; Koenig, W.; Shimokawa, H.;
Everett, B.M.; Glynn, R.J. Modulation of the interleukin-6 signalling pathway and incidence rates of
atherosclerotic events and all-cause mortality: Analyses from the canakinumab anti-inflammatory thrombosis
outcomes study (cantos). Eur. Heart J. 2018, 39, 3499–3507. [CrossRef]
84. Ridker, P.M.; MacFadyen, J.G.; Thuren, T.; Everett, B.M.; Libby, P.; Glynn, R.J. Effect of interleukin-1beta
inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results
from a randomised, double-blind, placebo-controlled trial. Lancet (Lond. Engl.) 2017, 390, 1833–1842.
[CrossRef]
85. Malaviya, A.N.; Sharma, A.; Agarwal, D.; Kapoor, S.; Garg, S.; Sawhney, S. Low-dose and high-dose
methotrexate are two different drugs in practical terms. Int. J. Rheum. Dis. 2010, 13, 288–293. [CrossRef]
86. Cutolo, M.; Sulli, A.; Pizzorni, C.; Seriolo, B.; Straub, R.H. Anti-inflammatory mechanisms of methotrexate in
rheumatoid arthritis. Ann. Rheum. Dis. 2001, 60, 729–735. [CrossRef]
87. Choi, H.K.; Hernan, M.A.; Seeger, J.D.; Robins, J.M.; Wolfe, F. Methotrexate and mortality in patients with
rheumatoid arthritis: A prospective study. Lancet (Lond. Engl.) 2002, 359, 1173–1177. [CrossRef]
88. Van Halm, V.P.; Nurmohamed, M.T.; Twisk, J.W.; Dijkmans, B.A.; Voskuyl, A.E. Disease-modifying
antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid
arthritis: A case control study. Arthritis Res. Ther. 2006, 8, R151. [CrossRef]
89. Naranjo, A.; Sokka, T.; Descalzo, M.A.; Calvo-Alen, J.; Horslev-Petersen, K.; Luukkainen, R.K.; Combe, B.;
Burmester, G.R.; Devlin, J.; Ferraccioli, G.; et al. Cardiovascular disease in patients with rheumatoid arthritis:
Results from the quest-ra study. Arthritis Res. Ther. 2008, 10, R30. [CrossRef]
J. Clin. Med. 2019, 8, 1109 19 of 20
90. Micha, R.; Imamura, F.; Wyler von Ballmoos, M.; Solomon, D.H.; Hernan, M.A.; Ridker, P.M.; Mozaffarian, D.
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am. J. Cardiol.
2011, 108, 1362–1370. [CrossRef]
91. Mallat, Z.; Lambeau, G.; Tedgui, A. Lipoprotein-associated and secreted phospholipases a(2) in cardiovascular
disease: Roles as biological effectors and biomarkers. Circulation 2010, 122, 2183–2200. [CrossRef]
92. Tschopp, J.; Schroder, K. Nlrp3 inflammasome activation: The convergence of multiple signalling pathways
on ros production? Nat. Rev. Immunol. 2010, 10, 210–215. [CrossRef]
93. Duewell, P.; Kono, H.; Rayner, K.J.; Sirois, C.M.; Vladimer, G.; Bauernfeind, F.G.; Abela, G.S.; Franchi, L.;
Nunez, G.; Schnurr, M.; et al. Nlrp3 inflammasomes are required for atherogenesis and activated by
cholesterol crystals. Nature 2010, 464, 1357–1361. [CrossRef]
94. Rajamaki, K.; Lappalainen, J.; Oorni, K.; Valimaki, E.; Matikainen, S.; Kovanen, P.T.; Eklund, K.K. Cholesterol
crystals activate the nlrp3 inflammasome in human macrophages: A novel link between cholesterol
metabolism and inflammation. PLoS ONE 2010, 5, e11765. [CrossRef]
95. Martinon, F.; Petrilli, V.; Mayor, A.; Tardivel, A.; Tschopp, J. Gout-associated uric acid crystals activate the
nalp3 inflammasome. Nature 2006, 440, 237–241. [CrossRef]
96. Zhou, W.; Chen, C.; Chen, Z.; Liu, L.; Jiang, J.; Wu, Z.; Zhao, M.; Chen, Y. Nlrp3: A novel mediator in
cardiovascular disease. J. Immunol. Res. 2018, 2018, 5702103. [CrossRef]
97. He, Y.; Hara, H.; Nunez, G. Mechanism and regulation of nlrp3 inflammasome activation. Trends Biochem.
Sci. 2016, 41, 1012–1021. [CrossRef]
98. Van Hout, G.P.; Bosch, L.; Ellenbroek, G.H.; de Haan, J.J.; van Solinge, W.W.; Cooper, M.A.; Arslan, F.;
de Jager, S.C.; Robertson, A.A.; Pasterkamp, G.; et al. The selective nlrp3-inflammasome inhibitor mcc950
reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur. Heart J. 2017,
38, 828–836. [CrossRef]
99. Van der Heijden, T.; Kritikou, E.; Venema, W.; van Duijn, J.; van Santbrink, P.J.; Slutter, B.; Foks, A.C.;
Bot, I.; Kuiper, J. Nlrp3 inflammasome inhibition by mcc950 reduces atherosclerotic lesion development in
apolipoprotein e-deficient mice-brief report. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 1457–1461. [CrossRef]
100. Huber, S.A.; Sakkinen, P.; Conze, D.; Hardin, N.; Tracy, R. Interleukin-6 exacerbates early atherosclerosis in
mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 2364–2367. [CrossRef]
101. Akita, K.; Isoda, K.; Sato-Okabayashi, Y.; Kadoguchi, T.; Kitamura, K.; Ohtomo, F.; Shimada, K.; Daida, H.
An interleukin-6 receptor antibody suppresses atherosclerosis in atherogenic mice. Front. Cardiovasc. Med.
2017, 4, 84. [CrossRef]
102. Kleveland, O.; Kunszt, G.; Bratlie, M.; Ueland, T.; Broch, K.; Holte, E.; Michelsen, A.E.; Bendz, B.;
Amundsen, B.H.; Espevik, T.; et al. Effect of a single dose of the interleukin-6 receptor antagonist
tocilizumab on inflammation and troponin t release in patients with non-st-elevation myocardial infarction:
A double-blind, randomized, placebo-controlled phase 2 trial. Eur. Heart J. 2016, 37, 2406–2413. [CrossRef]
103. Hirabayashi, Y.; Ishii, T.; Harigae, H. Clinical efficacy of tocilizumab in patients with active rheumatoid
arthritis in real clinical practice. Rheumatol. Int. 2010, 30, 1041–1048. [CrossRef]
104. Jones, S.A.; Scheller, J.; Rose-John, S. Therapeutic strategies for the clinical blockade of il-6/gp130 signaling.
J. Clin. Investig. 2011, 121, 3375–3383. [CrossRef]
105. Leung, Y.Y.; Yao Hui, L.L.; Kraus, V.B. Colchicine–update on mechanisms of action and therapeutic uses.
Semin. Arthritis Rheum. 2015, 45, 341–350. [CrossRef]
106. Demidowich, A.P.; Davis, A.I.; Dedhia, N.; Yanovski, J.A. Colchicine to decrease nlrp3-activated inflammation
and improve obesity-related metabolic dysregulation. Med. Hypotheses 2016, 92, 67–73. [CrossRef]
107. Verma, S.; Eikelboom, J.W.; Nidorf, S.M.; Al-Omran, M.; Gupta, N.; Teoh, H.; Friedrich, J.O. Colchicine in
cardiac disease: A systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc.
Disord. 2015, 15, 96. [CrossRef]
108. Crittenden, D.B.; Lehmann, R.A.; Schneck, L.; Keenan, R.T.; Shah, B.; Greenberg, J.D.; Cronstein, B.N.;
Sedlis, S.P.; Pillinger, M.H. Colchicine use is associated with decreased prevalence of myocardial infarction in
patients with gout. J. Rheumatol. 2012, 39, 1458–1464. [CrossRef]
109. Langevitz, P.; Livneh, A.; Neumann, L.; Buskila, D.; Shemer, J.; Amolsky, D.; Pras, M. Prevalence of ischemic
heart disease in patients with familial mediterranean fever. Isr. Med Assoc. J. IMAJ 2001, 3, 9–12.
J. Clin. Med. 2019, 8, 1109 20 of 20
110. Martínez, G.J.; Robertson, S.; Barraclough, J.; Xia, Q.; Mallat, Z.; Bursill, C.; Celermajer, D.S.; Patel, S.
Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute
coronary syndrome. J. Am. Heart Assoc. 2015, 4, e002128. [CrossRef]
111. Vaidya, K.; Arnott, C.; Martínez, G.J.; Ng, B.; McCormack, S.; Sullivan, D.R.; Celermajer, D.S.; Patel, S.
Colchicine therapy and plaque stabilization in patients with acute coronary syndrome. JACC Cardiovasc.
Imaging 2018, 11, 305–316. [CrossRef] [PubMed]
112. Nidorf, M.; Thompson, P.L. Effect of colchicine (0.5 mg twice daily) on high-sensitivity c-reactive protein
independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am. J. Cardiol. 2007,
99, 805–807. [CrossRef] [PubMed]
113. Hemkens, L.G.; Ewald, H.; Gloy, V.L.; Arpagaus, A.; Olu, K.K.; Nidorf, M.; Glinz, D.; Nordmann, A.J.;
Briel, M. Colchicine for prevention of cardiovascular events. Cochrane Database Syst. Rev. 2016. [CrossRef]
[PubMed]
114. Pillinger, M.H.; Krasnokutsky, S.; Slobodnick, A.; Shah, B. Update on colchicine, 2017. Rheumatology 2017, 57,
i4–i11.
115. Heuser, M.; Thol, F.; Ganser, A. Clonal hematopoiesis of indeterminate potential. Dtsch. Arztebl. Int. 2016,
113, 317–322. [CrossRef] [PubMed]
116. Jaiswal, S.; Fontanillas, P.; Flannick, J.; Manning, A.; Grauman, P.V.; Mar, B.G.; Lindsley, R.C.; Mermel, C.H.;
Burtt, N.; Chavez, A.; et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J.
Med. 2014, 371, 2488–2498. [CrossRef] [PubMed]
117. Jaiswal, S.; Natarajan, P.; Silver, A.J.; Gibson, C.J.; Bick, A.G.; Shvartz, E.; McConkey, M.; Gupta, N.; Gabriel, S.;
Ardissino, D.; et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med.
2017, 377, 111–121. [CrossRef]
118. Sano, S.; Oshima, K.; Wang, Y.; MacLauchlan, S.; Katanasaka, Y.; Sano, M.; Zuriaga, M.A.; Yoshiyama, M.;
Goukassian, D.; Cooper, M.A.; et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a
mechanism involving the il-1beta/nlrp3 inflammasome. J. Am. Coll. Cardiol. 2018, 71, 875–886. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
